Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Firefly Neuroscience (AIFF) EBIT (2016 - 2025)

Firefly Neuroscience has reported EBIT over the past 15 years, most recently at -$2.5 million for Q4 2025.

  • Quarterly results put EBIT at -$2.5 million for Q4 2025, up 27.21% from a year ago — trailing twelve months through Dec 2025 was -$8.9 million (up 11.92% YoY), and the annual figure for FY2025 was -$8.9 million, up 11.92%.
  • EBIT for Q4 2025 was -$2.5 million at Firefly Neuroscience, up from -$2.7 million in the prior quarter.
  • Over the last five years, EBIT for AIFF hit a ceiling of $793000.0 in Q4 2023 and a floor of -$4.3 million in Q3 2024.
  • Median EBIT over the past 5 years was -$1.1 million (2022), compared with a mean of -$1.2 million.
  • Biggest five-year swings in EBIT: soared 310.7% in 2021 and later tumbled 3062.76% in 2022.
  • Firefly Neuroscience's EBIT stood at -$165633.0 in 2021, then crashed by 511.3% to -$1.0 million in 2022, then soared by 178.32% to $793000.0 in 2023, then plummeted by 533.29% to -$3.4 million in 2024, then increased by 27.21% to -$2.5 million in 2025.
  • The last three reported values for EBIT were -$2.5 million (Q4 2025), -$2.7 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.